
Referências

Bibliográficas

7. REFERÊNCIAS BIBLIOGRÁFICAS

1. Shepard CC, McRae DH. *Mycobacterium leprae* in mice: minimal infectious dose, relationship between staining quality and infectivity, and effect of cortisone. *J Bacteriol* 1965; 89:365-72.
2. Rees RJW, Young DB. The microbiology of leprosy. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.49-83.
3. Srinivasan H. Disability deformity and rehabilitation. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.411-47.
4. Harboe M. Overview of host-parasite relations. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.87-112.
5. Newell KW. An epidemiologist's view of leprosy. *Bulletin of the World Health Organization* 1966; 34:827-57.
6. Job CK. Pathology of leprosy. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.193-224.
7. Ridley DS. *Skin biopsy in leprosy*, 2nd ed. Switzerland: CIBA-GEIGY; 1987.
8. Rabello FE. Clinical aspects: The polar concept. In: Latapi F, Saúl A, Rodriguez O, Browne SG. *Leprosy. Proceedings of the XI International Leprosy Congress*. Amsterdam: Excerpta Médica; 1978. p. 63-7.

9. Fleury RN. Dificuldades no emprego da classificação de Ridley e Jopling — uma análise morfológica. *Hans Int* 1989; 14(2):101-6.
10. Pfaltzgraff RE, Ramu G. Clinical Leprosy. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p. 237-87.
11. Ridley DS, Jopling WH. A classification of leprosy for research purposes. *Lepr Rev* 1962; 33:119-28.
12. Ridley DS, Jopling WH. Classification of leprosy according to immunity - a five- group system. *Int J Lepr* 1966; 34:255-73.
13. Krahenbuhl JL, Adams LB. The role of the macrophage in resistance to the leprosy bacillus. *Immunol Ser* 1994; 60:281-302.
14. Kirchheimer WF, Storrs EE. Attempts to establish the armadillo (*Dasypus novemcinctus Linn.*) as a model for the study of leprosy. *Int J Lepr* 1971; 39:693-702.
15. Meyers WM, Gormus BJ, Walsh GP. Experimental leprosy. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.385-410.
16. Hunter SW, Brennan, PJ. A novel phenolic glycolipid from *Mycobacterium leprae* possibly involved in immunogenicity and pathogenicity. *J Bacteriol* 1981; 147:728-35.
17. Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific antigen of *Mycobacterium leprae*. *J Biol Chem* 1982; 257:15072-8.

18. Neill MA, Klebanoff SJ. The effect of phenolic glycolipid-I from *Mycobacterium leprae* on the antimicrobial activity of human macrophages. J Exp Med 1988; 167:30-42.
19. Vachula M, Worobec S, Andersen BR. A comparison of monocyte oxidative responses in leprosy patients and healthy subjects as influenced by mycobacterial lipid treatment. Int J Lepr 1990; 58:534-9.
20. Silva CL, Faccioli LH, Foss NT. Suppression of human monocyte cytokine release by phenolic glycolipid-1 of *Mycobacterium leprae*. Int J Lepr 1993; 61(1):107-8.
21. Mehra V, Brennan PJ, Rada E, Convit J, Bloom BR. Lymphocyte suppression in leprosy induced by unique M. *leprae* glycolipid. Nature 1984; 308:194-6.
22. Prasad HK, Mishra RS, Nath I. Phenolic glycolipid-1 of *Mycobacterium leprae* induces general suppression of *in vitro* concanavalin A responses unrelated to leprosy type. J Exp Med 1987; 165:239-44.
23. Roitt I, Brostoff J, Male D. Imunidade as bactérias e aos fungos. In: Imunologia 5ª ed. São Paulo:Manole; 1999. p.229-42.
24. Lockwood DNJ, Colston MJ, Khanolkar-Young SR. The detection of *Mycobacterium leprae* protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002; 66(4):409-15.
25. Van den Bos IC, Khanolkar-Young S, Das PK, Lockwood DNJ. Immunohistochemical detection of PGL-1, LAM, 30kD and 65 kD

- antigens in leprosy infected paraffin preserved skin and nerve sections. *Lepr Rev* 1999; 70:272-80.
26. Verhagen CE, Faber W, Klatser P, Buffing A, Naafs B, Das PK. Immunohistological analysis of *in situ* expression of mycobacterial antigens in skin lesions of leprosy patients across the histopathological spectrum. Association of mycobacterium lipoarabinomannan (LAM) and *Mycobacterium leprae* phenolic glycolipid-I (PGL-I) with leprosy reactions. *Am J Pathol* 1999; 154:1793-804.
27. Narayanan RB, Girdhar BK, Malaviya GN, Sengupta U. *In situ* demonstration of *Mycobacterium Ieprae* antigens in leprosy lesions using monoclonal antibodies. *Immunology Lett* 1990; 24:179-84.
28. Wang T, Izumi S, Butt KI, Kawatsu K, Maeda Y. Demonstration of PGL-1 and LAM-B antigens in paraffin sections of leprosy skin lesions. *Jpn J Leprosy* 1992; 61:161-74.
29. Shetty VP, Uplekar MW, Anita NH. Immunohistological localization of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. *Acta Neuropathol* 1994; 88:300-6.
30. Natrajan M, Katoch K, Katoch VM. Histology and immuno-histology of lesions clinically suspicious of leprosy. *Acta Leprologica* 1999; 11(3):93-8.
31. Takashashi MD, Anrade Jr HF, Wakamatsu A, Siqueira S, De Brito T. Indeterminate leprosy: histopathological and histochemical predictive parameters involved in its possible change to paucibacillary or multibacillary leprosy. *Int J Lepr* 1991; 59(1):12-9.

32. Barbosa Jr AA, Silva T C, Patel BN, Santos MIR, Wakamatsu A, Alves VAF. Demonstration of mycobacterial antigens in skin biopsies from suspected leprosy cases in the absence of bacilli. *Path Res Pract* 1994; 190:782-5.
33. Schettini APM, Ferreira LCL, Milagros R, Schettini MCA, Pennini SN, Rebello PB. Enhancement in the histological diagnosis of leprosy in patients with only sensory loss by demonstration of mycobacterial antigens using anti-BCG polyclonal antibodies. *Int J Lepr* 2001; 69(4):335-40.
34. Fakhouri R, Sotto MN, Manini MIP, Margarido LC. Nodular leprosy of childhood and tuberculoid leprosy: a comparative, morphologic, immunopathologic and quantitative study of skin tissue reaction. *Int J. Lepr* 2003; 71(3):218-26.
35. Pagliari C, Duarte MIS, Sotto MN. Pattern of mycobacterial antigen detection in leprosy. *Rev Inst Med Trop São Paulo* 1995; 37(1):712.
36. Kutzner H, Argenyi ZB, Requena L, Rütten A, Hügel H. A new application of BCG antibody for rapid screening of various tissue microorganisms. *J Am Acad Dermatol* 1998; 38(1):56-60.
37. Mims CA. *The pathogenesis of infectious diseases*, 2nd ed. London:Academic Press; 1982.
38. Modlin RL. Learning from leprosy: insights into contemporary immunology from an ancient disease. *Skin Pharmacol Appl Skin Physiol* 2002; 15:1-6.

39. Roitt I, Brostoff J, Male D. Células Envolvidas nas Respostas Imunes. In: *Imunologia* 5ª ed. São Paulo: Manole; 1999. p.13-30.
40. Goldsby RA., Kindt TJ, Osborne BA. *Kuby Imunologia* 4ª ed. Rio de Janeiro: Revinter; 2002. p.239-67.
41. Kaufmann SHE. Cell-mediated immunity. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.157-68.
42. Modlin RL, Rea, TH. Immunopathology of leprosy. In: Hastings, RC, editor. *Leprosy*, 2nd ed. New York: Churchill Livingstone; 1994. p.225-34.
43. Ernst WA, *et al.* Granulysin, a T cell product, kills bacteria by altering membrane permeability. *J Immunol* 2000; 165:7102-8.
44. Modlin RL. Th1-Th2 paradigm: insights from leprosy. *J Invest Dermatol* 1994; 102:828-32.
45. Garcia VE, *et al.* IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. *J Immunol* 1999; 162(10):6114-21.
46. Trincheri G, Matsumoto-Kobayashi M, Clark SC, Sheera J, London L, Perrussia B. Response of resting human peripheral blood natural killer cells to interleukin-2. *J Experiment Med* 1984; 60:1147-69.
47. Cuturi MC, *et al.* Production of hematopoietic colony-stimulating factors by human natural killer cells. *J Experiment Med* 1989; 69:569-83.

48. Chan SH, *et al.* Induction of γ -IFN production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with others inducers. *J Experiment Med* 1991; 173(4):869-79.
49. Romagnani S. Induction of Th1 and Th2 responses: a key role for the "natural" immune response? *Immunol Today* 1992; 13(10):37981.
50. Modlin RL, Hofman FM, Taylor CR, Rea TH. T lymphocyte subsets in the skin lesion of patients with leprosy. *J Am Acad Dermatol* 1983; 8:182-9.
51. Narayanan RB, Bhutani LK, Sharma AK, Nath I. T cell subsets in leprosy lesions: *in situ* characterization using monoclonal antibodies. *Clin Exp Immunol* 1983; 51:421-9.
52. Kato H, Sanada K, Koseki M, Ozawa T. Identification lymphocyte subpopulations in cutaneous lesions of leprosy. *Jpn J Leprosy* 1983; 52:126-32.
53. Modlin RL, *et al.* Learning from lesions: patterns of tissue inflammation in leprosy. *Proc Natl Acad Sci USA* 1988; 85:1213-7.
54. De la Barrera S, *et al.* NK cells modulate the cytotoxic activity generated by *Mycobacterium leprae-hsp65* in leprosy patients: role of IL-18 and IL-13. *Clin Exp Immunol* 2004; 135(1): 105-13.
55. Mosmann TR, Cherwinsky H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I - Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986; 136(7): 2348-57.

56. Yamamura M, *et al.* Defining protective responses to pathogens: cytokine profiles in leprosy lesions. *Science* 1991; 254(5029): 2779.
57. Sieling PA, Modlin RL. T cell and cytokine patterns in leprosy skin lesions. *Springer Semin Immunopathol* 1992; 13:413-26.
58. Sieling PA, Modlin RL. T Cytokine patterns in leprosy. *Ann NY Acad Sci* 1994; 730:42-52, 1994.
59. Sieling PA, *et al.* Immunosuppressive roles for IL-10 and IL-4 in human infection. *J Immunol* 1993; 150(12):5501-10.
60. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokines production by Th1 clones. *J Exp Med* 1989; 170: 2081-95.
61. Mosmann TR. Regulation of immune responses by T cells with different cytokine secretion phenotypes: role of a new cytokine, Cytokine Synthesis Inhibitory Factor (IL-10). *Int Arch Allergy and Applied Immunol* 1991; 94(1-4):110-5.
62. Bogdan C, Paik J, Vodovotz Y, Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor- β and interleukin-10. *J Biol Chem* 1992; 267(32):23301-8.
63. Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor- β , interleukin-4, and interleukin-10. *Ann NY Acad Sci* 1993; 685:713-39.

64. Weiss E, *et al.* The role of interleukin 10 in the pathogenesis and potential treatment of skin diseases. *J Am Acad Dermatol* 2004; 50:657-75.
65. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL- 10 inhibits cytokine production by activated macrophages. *J Immunol Baltimore* 1991; 147(11):3815-22.
66. Gazzinelli RT, Oswald IP, James SL, Scher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN- γ -activated macrophages. *J Immunol* 1992; 148(6):1792-6.
67. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-12 production. *J Immunol* 1992; 148(4):1143-8.
68. Fukutomi Y, Matsuoka M, Minagawa F, Toratani S, McCormick G, Krahenbuhl J. IL-10 treatment of macrophages bolsters intracellular survival of mycobacterium leprae. *Int J Lepr* 2004; 72(1):16-26.
69. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. *J Immunol* 1993; 150(2):353-60.
70. Roitt I, Brostoff J, Male D. *Imunologia* 5^a ed. São Paulo: Manole, 1999, p.139-53.
71. Khanolkar-Young S, Snowdon D, Lockwood DNJ. Immunocytochemical localization of inducible nitric oxide synthase

- and transforming growth factor-beta (TFG- β) in leprosy lesions. Clin Exp Immunol 1998; 113:438-42.
72. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329(27):2002-12.
73. Schön T, Hernandez-Pando RH, Negesse Y, Leekassa R, Sundqvist T, Britton S. Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions. Br J Dermatol 2001; 145:809-15.
74. Ross R, *et al.* Involvement of NO in contact hypersensitivity. Int Immunol 1998; 10(1):61-9.
75. Oliveira SH, Fonseca SG, Romão PR, Figueiredo F, Ferreira SH, Cunha FQ. Microbicidal activity of eosinophils is associated with activation of the arginine-NO pathway. Parasite Immunol 1998; 20(9):405-12.
76. Takeichi O, Saito I, Okamoto Y, Tsurumachi T, Saito T. Cytokine regulation on the synthesis of nitric oxide in vivo by chronically infected human polymorphonuclear leucocytes. Immunology 1998; 93(2):275-80.
77. Taylor-Robinson AW, *of al.* Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24(4):980-4.
78. Fox SW, Chow JW. Nitric oxide synthase expression in bone cells. Bone 1998; 23(1):1-6.

79. Moncada S, Palmer RM, Higgs A. Nitric oxide: physiology, pathophysiology and pharmacology. *Pharmacol Rev* 1991; 43(2):109-42.
80. Liew FY. The role of nitric oxide in parasitic disease. *Ann Trop Med Parasitol* 1993; 87(6):634-42.
81. Goulart IMB, Figueiredo F, Coimbra T, Foss NT. Detection of transforming growth factor- β 1 in dermal lesions of different clinical forms of leprosy. *Am J Pathol* 1996; 148:911-7.
82. Facchetti F, *et al.* Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. *Am J Pathol* 1999; 154(1):145-52.
83. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DNJ. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. *Infect Immun* 2001; 69(5):3413-7.
84. Sicher SC, Vazquez MA, Lu CY. Inhibition of macrophage Ia expression by nitric oxide. *J Immunol* 1994; 153(3):1293-300.
85. Faget GH, Pogge RC, Johansen FA, Dinan JF, Prejean BM, Eccles CG. The Promin treatment of leprosy: a progress report. *Pub Health Rep* 1943; 58:1729-41.
86. Organização Mundial De Saúde. Quimioterapia da hanseníase para programas de controle. (Série de Relatórios Técnicos, 675). Genebra: OMS; 1982.

87. Floch H. La sulfono-résistance du bacilli de Hansen. Arch L'Institut Pasteur 1957; 429:1-9.
88. Pettit JHS., Rees RJW. Sulphone resistance in leprosy: an experimental and clinical study. Lancet 1964; 2:673-4.
89. Opromolla DVA, Souza Lima L, Caprara G. Rifamycin SV in the treatment of lepromatous leprosy. Lepr Rev 1965; 36:123-31.
90. Trindade MAB. Evolução histológica de reativações da hanseníase durante ou após o tratamento [Tese de Doutorado]. São Paulo: Escola Paulista de Medicina — UNIFESP; 1996.
91. Jacobson RR, Hastings RC. Rifampin-resistant leprosy [Letter]. Lancet 1976; 2:1304.
92. Jacobson RR. Treatment of leprosy. In: Hastings RC, editor. Leprosy 2nd ed. New York: Churchill Livingstone; 1994. p.317-49.
93. Ministério da Saúde — Guia para o Controle da Hanseníase. Cadernos de Atenção Básica — número 10. Brasília: Ministério da Saúde; 2002.
94. Opromolla DVA, Fleury RN. Classification of leprosy. In: Latapi F, Saúl A, Rodriguez O, Browne SG. Leprosy. Proceedings of the XI International Leprosy Congress. Amsterdam: Excerpta Médica; 1978. p. 254-60.
95. Opromolla DVA. Alguns comentários acerca de um caso relatado por Wade e Rodriguez nos anos 30. Hansen Int 1995; 20:29-37.

96. Naafs B, Wheate HW. The time interval between the start of anti-leprosy treatment and the development of reactions in borderline patients. *Lepr Rev* 1978; 49:153-7.
97. Souza Campos N, Rath de Souza, P. Reactional states in leprosy. *Int J Lepr* 1954; 22:259-73.
98. Jopling WH. Leprosy reactions (reactional states). In: *Handbook of leprosy* 2nd ed. London: William Heinemann Med. Books; 1978. p.66-74.
99. Souza Lima L, Souza Campos N. *Lepra tuberculóide: estudo clínico-histopatológico*. São Paulo: Renascença; 1947.
100. Dharmendra. Classification of leprosy. In: Hastings RC, editor. *Leprosy* 2nd ed. New York: Churchill Livingstone; 1994. p.179-90.
101. Wade HW. Tuberculoid changes in leprosy: II Lepra reaction in tuberculoid leprosy. *Int J Lepr* 1934; 2:279-92.
102. Lastoria JC, Opromolla DVA, Fleury RN, Habermann F, Curi PR. Serial Mitsuda testes for identification of reactional borderline leprosy forms. *Int J Lepr* 1998; 66(2):190-200.
103. Shelly VP, Wakade A, Antia NH. High incidence of viable *Mycobacterium leprae* in post-MDT recurrent lesions in tuberculoid leprosy patients. *Lepr Rev* 2001; 72:337-44.
104. Desikan ITV. Relapse, reactivation or reinfection? [Symposium paper]. *Indian J Lepr* 1995; 67:3-11.

105. Job CK. Histopathological features of relapsed leprosy [Symposium paper]. *Indian J Lepr* 1995; 67:69-80.
106. Opromolla DVA. As reações tipo I [Editorial]. *Hansen Int* 2001; 26: 89-90.
107. Waters MFR. Distinguishing between relapse and late reversal reaction in multidrug (MDT)-treated BT leprosy [Editorial]. *Lepr Rev* 2001; 72:250-3.
108. Ridley DS, Radia KB. The histological course of reactions in borderline leprosy and their outcome. *Int J Lepr* 1981; 49:383-92.
109. Becx-Bleuminck M. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the all Africa leprosy and rehabilitation training center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. *Int J Lepr* 1992; 60:421-35.
110. Yamamura M, *et al.* Cytokine patterns of immunologically mediated tissue damage. *J Immunol* 1992; 149(4):1470-5.
111. Verhagen CE, *et al.* Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like *Mycobacterium leprae* T-cell reactivity in lesional skin. *J Immunol* 1997; 159:14705.
112. Atkinson SE, *et al.* Detection of IL-13, IL-10, and IL-6 in the leprosy skin lesions of patients during prednisolone treatment for type 1 (Ti R) reactions. *Int J Lepr* 2004; 72(1):27-34.

113. Converse PJ., Bjune G. Natural killer (NK) cell activity and reversal reaction in leprosy. *Int J Lepr Other Mycobact Dis* 1986; 54(4):503-9.
114. Rijk AJ, Gabre S, Byass P, Berhanu T. Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project: II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. *Lepr Rev* 1994; 65:320-32.
115. Lockwood DNJ, Vinayakumar S, Stanley JNA, McAdam KPWJ, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. *Int J Lepr* 1993; 61:8-15.
116. Roche PW, Theuvenet WJ, Britton WJ. Risk factors for type 1 reactions in borderline leprosy patients. *Lancet* 1991; 338:654-57.
117. Godal T, Myrvang B, Samuel DR, Ross WF, Lofgren M. Mechanism of "reactions" in borderline tuberculoid (BT) leprosy. *Acta Path Microbiol Scand* 1973; 236 Suppl A:45-53.
118. Bjune G, Barnetson RStC, Ridley DS, Kronvall G. Lymphocyte transformation test in leprosy: correlation of response with inflammation of lesions. *Clin Exp Immunol* 1976; 25:85-94.
119. Opromolla DVA, Fleury RN. Classification of leprosy. In: Latapi F, Saúl A, Rodriguez O, Browne SG. *Leprosy. Proceedings of the XI International Leprosy Congress*. Amsterdam: Excerpta Médica; 1978. p. 254-60.
120. Starlz TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. *N Engl J Med* 1998; 339(26):1905-13.

121. Belone AFF. Hanseníase na faixa tuberculóide: estudo comparativo entre manifestações tórpidas e reacionais através de avaliações de antígenos micobacterianos e de parâmetros representativos de hipersensibilidade mediada por células, em biópsias cutâneas. [Tese de Doutorado]. São Paulo: Universidade Estadual Paulista — UNESP; 2004.